Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection
Conclusions Omalizumab use for asthma has been gradually decreasing following a peak shortly after its market availability. Many omalizumab users have low or very low adherence rates for ICSs and/or ICS-LABA in the 12 months before omalizumab initiation.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Corticosteroid Therapy | Databases & Libraries | Insurance | Lessons | Medicare | Xolair